Drugs / LTG-305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06554574 | Sep 2024 → Jun 2025 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-16 | Latigo Biotherapeutics | Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain latigobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTG-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06554574 ↗ |
| Route | Oral | “orally administered LTG-305” NCT06554574 ↗ |